Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)-Reference-Cited by-同舟云学术

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)

Published:2016-12 Issue:24 Volume:26 Page:5947-5950
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Lam Betty,Arikawa Yasuyoshi,Cramlett Joshua,Dong Qing,de Jong Ron,Feher Victoria,Grimshaw Charles E.,Farrell Pamela J.,Hoffman Isaac D.,Jennings Andy,Jones Benjamin,Matuszkiewicz Jennifer,Miura Joanne,Miyake Hiroshi,Natala Srinivasa Reddy,Shi Lihong,Takahashi Masashi,Taylor Ewan,Wyrick Corey,Yano Jason,Zalevsky Jonathan,Nie Zhe

Funder

Office of Science, Office of Basic Energy Sciences, Materials Sciences Division, of the U.S. Department of Energy

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference33 articles.

1. Structure and Function of Syk Protein-Tyrosine Kinase

2. Targeting Syk as a treatment for allergic and autoimmune disorders

3. Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma

4. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

5. SYK inhibition and response prediction in diffuse large B-cell lymphoma

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents;Expert Opinion on Investigational Drugs;2024-08-11

2. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors;ESMO Open;2024-06

3. A novel natural Syk inhibitor suppresses IgE-mediated mast cell activation and passive cutaneous anaphylaxis;Bioorganic Chemistry;2024-05

4. Identification and structural characterization of small molecule inhibitors of PINK1;Scientific Reports;2024-04-02

5. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors;Cancer Medicine;2024-03